Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:10:55.177Z.
Calculation as of: 2026-10-06T14:10:55.177Z.
Quote observation: 2026-10-06T14:10:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47c8a7f7872550f4b91559d6c77d4467729e005a9c3786f3e3eb9faa26d80d2a
PEG RATIO
N/A
Market Cap
$716.11M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$715.49M
PEG Ratio
0.99
TTM Avg
1.06
3Y Avg
1.06
5Y Avg
1.06
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $719.62M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $716.11M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 0.99 | 1.06 | 1.06 | 1.06 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $740.03M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $762.81M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $769.83M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute